We are live on
!
Find out more
TCG Crossover Management Portfolio holdings
AUM
$4.16B
Turnover
31.15%
1-Year Est. Return
983.43%
This Fund
S&P 500
This Quarter
Est. Return
+83.13%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$567M
AUM Growth
+$233M
(+70%)
Cap. Flow
+$110M
Cap. Flow
% of AUM
19.49%
Top 10 Holdings %
Top 10 Hldgs %
79.55%
Holding
26
New
5
Increased
7
Reduced
4
Closed
5
Avg Time Held
0.6
years
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$27M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$25.2M |
| 3 |
Ventyx Biosciences
VTYX
|
+$23.3M |
| 4 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$18.8M |
| 5 |
KalVista Pharmaceuticals
KALV
|
+$18.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Allakos
ALLK
|
+$10.1M |
| 2 |
AKUS
Akouos Inc
AKUS
|
+$9.13M |
| 3 |
Tango Therapeutics
TNGX
|
+$4.24M |
| 4 |
Viridian Therapeutics
VRDN
|
+$4.16M |
| 5 |
Dianthus Therapeutics
DNTH
|
+$3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
ISEE
1
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $110M | 19.43% |
5,141,118
+1,263,215
| +33% | +$27M |
2021 Q4
4 quarters
|
|
|
2
Madrigal Pharmaceuticals
MDGL
$10.6B
| $83.6M | 14.76% |
288,054
+258,054
| +860% | +$25.2M |
2022 Q3
1 quarter
|
|
3
Cogent Biosciences
COGT
$4.88B
| $42M | 7.41% |
3,631,042
+150,000
| +4% | +$1.86M |
2021 Q4
4 quarters
|
|
4
DELISTED
Cymabay Therapeutics
CBAY
| $37M | 6.53% |
5,905,400
| – | – |
2021 Q4
4 quarters
|
|
5
Geron
GERN
$765M
| $36.8M | 6.49% |
15,187,073
+3,071,147
| +25% | +$6.88M |
2022 Q1
3 quarters
|
|
6
Silence Therapeutics
SLN
$558M
| $32.1M | 5.67% |
2,104,875
| – | – |
2022 Q3
1 quarter
|
|
7
Jade Biosciences
JBIO
$855M
| $31.7M | 5.59% |
30,894
+3,478
| +13% | +$2.53M |
2021 Q4
4 quarters
|
|
|
8
Viridian Therapeutics
VRDN
$2.08B
| $28.7M | 5.07% |
983,610
-180,390
| -15% | -$4.16M |
2021 Q4
4 quarters
|
|
|
9
DELISTED
Ventyx Biosciences
VTYX
| $25.8M | 4.56% |
+787,231
| New | +$23.3M |
2022 Q4
0 quarters
|
|
|
10
DELISTED
KalVista Pharmaceuticals
KALV
| $23M | 4.05% |
+3,395,495
| New | +$18.2M |
2022 Q4
0 quarters
|
|
|
VECT
11
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $20.2M | 3.57% |
+2,333,300
| New | +$18.8M |
2022 Q4
0 quarters
|
|
12
Aclaris Therapeutics
ACRS
$498M
| $18M | 3.18% |
1,144,939
| – | – |
2021 Q4
4 quarters
|
|
13
Kura Oncology
KURA
$855M
| $17.7M | 3.12% |
1,423,642
+75,000
| +6% | +$1.09M |
2022 Q1
3 quarters
|
|
14
Immunovant
IMVT
$5.76B
| $15.2M | 2.68% |
+854,853
| New | +$10.8M |
2022 Q4
0 quarters
|
|
15
Tyra Biosciences
TYRA
$1.29B
| $15.1M | 2.67% |
1,989,103
+1,043,396
| +110% | +$7.38M |
2021 Q4
4 quarters
|
|
16
MoonLake Immunotherapeutics
MLTX
$863M
| $10.5M | 1.85% |
1,000,000
| – | – |
2022 Q2
2 quarters
|
|
17
Entrada Therapeutics
TRDA
$177M
| $7.91M | 1.4% |
584,955
-57,234
| -9% | -$1M |
2021 Q4
4 quarters
|
|
18
DELISTED
Merus
MRUS
| $4.64M | 0.82% |
300,000
| – | – |
2021 Q4
4 quarters
|
|
19
Cabaletta Bio
CABA
$275M
| $4.5M | 0.79% |
+486,795
| New | +$1.77M |
2022 Q4
0 quarters
|
|
20
DELISTED
Alpine Immune Sciences Inc
ALPN
| $1.86M | 0.33% |
253,069
-1,500
| -0.6% | -$9.59K |
2021 Q4
4 quarters
|
|
21
DELISTED
Elevation Oncology
ELEV
| $274K | 0.05% |
288,390
-266,610
| -48% | -$271K |
2021 Q4
4 quarters
|
|
|
22
DELISTED
Allakos
ALLK
| – | – |
-1,643,500
| Closed | -$10.1M | – |
|
|
23
Dianthus Therapeutics
DNTH
$4.18B
| – | – |
-132,758
| Closed | -$3M | – |
|
|
24
Tango Therapeutics
TNGX
$3.74B
| – | – |
-1,172,250
| Closed | -$4.24M | – |
|
25
Zai Lab
ZLAB
$2.53B
| – | – |
-72,777
| Closed | -$2.49M | – |
|
Similar funds
CCMIC
TCG Crossover Management's Q4 2022 Portfolio in Review
As of Q4 2022, TCG Crossover Management held 26 positions worth $567M, up 70% from $333M the previous quarter. Its ten largest holdings account for 80% of the portfolio.
TCG Crossover Management deployed $110M of net new capital in Q4 2022, opening 5 new positions and adding to 7 existing holdings. Its largest new stake was Ventyx Biosciences: 787,231 shares worth $25.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Viridian Therapeutics, an estimated $4.16M trimmed.
- TCG Crossover Management's largest Q4 2022 buy was Ventyx Biosciences: 787,231 shares worth $25.8M.
- TCG Crossover Management added most to IVERIC bio, Inc. Common Stock in Q4 2022, an estimated $27M increase.
- TCG Crossover Management's biggest Q4 2022 reduction was Viridian Therapeutics, cutting an estimated $4.16M.
- TCG Crossover Management fully exited Allakos in Q4 2022, selling an estimated $10.1M.
- TCG Crossover Management's ten largest holdings make up 80% of its $567M portfolio in Q4 2022.
- TCG Crossover Management opened 5 new positions and closed 5 in Q4 2022.
- TCG Crossover Management's portfolio value rose 70% quarter-over-quarter to $567M.
Based on TCG Crossover Management's 13F filing for Q4 2022, filed 14 Feb 2023.